ACTRN12617000635369已完成未知
A single-centre centre randomized 6-week parallel group study of two different schedules of caloric restriction on resting energy expenditure in New Zealand men with a BMI >30 kg/m2.
Assoc Prof Jeremy Krebs0 个研究点目标入组 36 人开始时间: 2017年5月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
2 期
Effectiveness of physiotherapy combined with standard Ayurveda treatments (a personalized treatment regime with a combination of Kashaya, Arishta, pills and oils) versus physiotherapy with placebo in improving functional activities in ischemic stroke patients: A Randomized Controlled TrialIschemic strokeSLCTR/2021/021Higher degree, Research and Publication Committee
已完成
3 期
BE study of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg inhalation product in asthma patientCTRI/2022/08/044640Cipla Ltd1,191
进行中（未招募）
1 期
Combination treatment with dapagliflozin and exenatide to investigate the effect of weight loss in subjects with obesity compared to placebo.Obesity defined as body mass index (BMI) 30-45 kg/m2Obesity related metabolic disordersMedDRA version: 18.0Level: LLTClassification code 10029885Term: Obesity, unspecifiedSystem Organ Class: 100000004861EUCTR2014-003432-39-SEDept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
进行中（未招募）
不适用
A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phaseEUCTR2011-002969-38-DEovartis Pharma GmbH
未知
4 期
A 16-week Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on InsuliType 2 Diabetes MellitusJPRN-jRCT1080222537AstraZeneca